New FDA-authorized treatment PursueCare recently launched RESET and RESET-O, the only FDA-authorized digital therapeutics for substance use disorder and opioid use disorder. Highlighting this unique offering can attract health systems, insurers, and employers looking to provide cutting-edge treatment options for addiction and mental health.

Expansion into new markets With PursueCare expanding its services to various states, such as CT, KY, MA, ME, NH, NJ, OH, PA, and WV, there is an opportunity to target healthcare providers and facilities in these regions for partnerships. Customizing outreach strategies for each location can help increase market penetration and patient reach.

Partnerships with pharmaceutical companies By collaborating with pharmaceutical companies like Ascend Laboratories, PursueCare strengthens its position in the industry. Leveraging these partnerships can lead to cross-promotional opportunities, enabling PursueCare to tap into a broader network of patients seeking specialized addiction treatment and medication management.

Recognition in industry awards Being recognized as a rising star in mental and behavioral health at the Digital Health Hub awards signifies industry acknowledgment of PursueCare's innovative approach. This accolade can be utilized to enhance brand reputation and credibility, attracting potential partners and investors impressed by the company's contributions to the healthcare landscape.

Strong financial backing With a Series A funding round of $11 million and a revenue range of $10-50 million, PursueCare demonstrates financial stability and growth potential. This information can be leveraged in discussions with potential investors, showcasing the company's ability to scale operations and continue expanding its reach in the mental health care market.